From: Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Parameter | Adjusted HR | 95% CI |
---|---|---|
Drug therapy | ||
Non-TNF biologic ± DMARDs | Reference | – |
DMARDs | 0.80 | 0.62–1.03 |
TNFi ± DMARDs | 1.14 | 0.95–1.37 |
Tofacitinib ± DMARDs | 1.54 | 0.93–2.56 |
Current use of methotrexatea | 1.19 | 1.04–1.37 |
Previous use of biologicsa | 1.32 | 1.12–1.57 |
Previous use of other DMARDsa | 1.04 | 0.86–1.27 |
Sex (female) | 1.02 | 0.87–1.18 |
Age | 1.04 | 1.03–1.04 |
Year of cohort entry | ||
2011 | Reference | – |
2012 | 1.10 | 0.92–1.31 |
2013 | 0.85 | 0.66–1.08 |
2014 | 0.97 | 0.70–1.35 |
Oral glucocorticoid use one year prior to cohort entry | ||
No use | Reference | – |
Use of ≤ 7.5 mg/day of prednisone equivalent dose | 1.23 | 1.05–1.44 |
Use of > 7.5 mg/day of prednisone equivalent dose | 1.36 | 1.00–1.84 |
Current use of oral glucocorticoida | ||
No use | Reference | – |
Use of ≤ 7.5 mg/day of prednisone equivalent dose | 1.90 | 1.64–2.20 |
Use of > 7.5 mg/day of prednisone equivalent dose | 2.83 | 1.37–5.83 |
Nonsteroidal anti-inflammatory drugs use 1 year prior to cohort entry | 0.93 | 0.81–1.06 |
Selective COX-2 inhibitors use 1 year prior to cohort entry | 1.13 | 0.95–1.35 |
Charlson comorbidity index 1 year prior to cohort entry | 1.72 | 1.49–1.99 |
Infection related hospitalization 1 year prior to cohort entry | 2.19 | 1.68–2.86 |
Number of emergency department visits 1 year prior to cohort entry | 1.04 | 1.01–1.06 |
Number of physician visits 1 year prior to cohort entry | 1.01 | 1.00–1.01 |
Number of rheumatology visits 1 year prior to cohort entry | 1.00 | 0.99–1.02 |
Number of hospitalizations 1 year prior to cohort entry | 1.33 | 1.24–1.43 |